Cart
sales@molnova.com
AZD-3759
CAS No. 1626387-80-1
AZD-3759( AZD-3759 )
Catalog No. M12405 CAS No. 1626387-80-1
A potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 25MG | 35 | In Stock |
|
| 50MG | 49 | In Stock |
|
| 100MG | 77 | In Stock |
|
| 200MG | 113 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD-3759
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).
-
DescriptionA potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR); fully penetrate the blood-brain barrier (BBB), with equal free concentrations in the blood, cerebrospinal fluid, and brain tissue; causes tumor regression in subcutaneous xenograft, leptomeningeal metastasis (LM), and brain metastasis (BM) lung cancer models and prevents the development of BM in nude mice.Lung Cancer Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsAZD-3759
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR(exon19Del)|EGFR(L858R)|EGFR(WT)
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1626387-80-1
-
Formula Weight459.9011
-
Molecular FormulaC22H23ClFN5O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(N1[C@H](C)CN(C)CC1)OC2=CC3=C(NC4=CC=CC(Cl)=C4F)N=CN=C3C=C2OC
-
Chemical Name1-Piperazinecarboxylic acid, 2,4-dimethyl-, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester, (2R)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zeng Q, et al. J Med Chem. 2015 Oct 22;58(20):8200-15.
2. Yang Z, et al. Sci Transl Med. 2016 Dec 7;8(368):368ra172.
3. Tan CS, et al. Lung Cancer. 2016 Mar;93:59-68.
molnova catalog
related products
-
Canertinib dihydroch...
A potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay.
-
Petosemtamab
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells.
-
Theliatinib
Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.
